Results 51 to 60 of about 3,869 (167)
Cardiovascular Therapeutics, Volume 2026, Issue 1, 2026.Background Patients with advanced heart failure (AdHF) face a high risk of early readmission, leading to poor outcomes and increased healthcare burden. Early identification of high‐risk individuals remains a clinical challenge. Methods This retrospective study included 769 AdHF patients from the Affiliated Hospital of Xuzhou Medical University, with an
Baohe Zang +4 more
wiley +1 more source
Cardiovascular Therapeutics, Volume 2026, Issue 1, 2026.Background In cardiogenic shock (CS), titration of both the choice and dosage of inotropes and vasopressors is crucial. The vasoactive–inotropic score (VIS) quantifies hemodynamic support, while the effect of temporal VIS change on prognosis remains unclear. This study evaluated the association between the vasoactive–inotropic score reduction rate (VRR)
Yi-Le Ning +9 more
wiley +1 more source
Levosimendan: Perpetuum mobile? [PDF]
European Heart Journal, 2007 We read with great interest the well-written review about levosimendan by De Luca et al. 1 Levosimendan is certainly an interesting drug that appears to deliver favourable effects in patients with acute heart failure. Numerous studies have demonstrated the positive inotropic …
Stefan, Agewall, Dan, Atar
openaire +2 more sources
Revealing the Hidden Severity: A Case Report on Managing Complex Aortic Stenosis With TAVI
Case Reports in Cardiology, Volume 2026, Issue 1, 2026.Aortic stenosis (AS) is a progressive condition prevalent in older adults, with severity determined through clinical evaluation and imaging. However, diagnostic dilemmas arise when imaging results conflict with clinical symptoms. This report examines an 84‐year‐old male with chronic kidney disease, prior abdominal aortic aneurysm repair and other ...
Thomas Stefoulis +5 more
wiley +1 more source
Levosimendan in Cardiac Surgery [PDF]
New England Journal of Medicine, 2017 Comment on : Landoni G, Lomivorotov VV, Alvaro G, Lobreglio R, Pisano A, Guarracino F, Calabrò MG, Grigoryev EV, Likhvantsev VV, Salgado-Filho MF, Bianchi A, Pasyuga VV, Baiocchi M, Pappalardo F, Monaco F, Boboshko VA, Abubakirov MN, Amantea B, Lembo R, Brazzi L, Verniero L, Bertini P, Scandroglio AM, Bove T, Belletti A, Michienzi MG, Shukevich DL ...
Putzu, Alessandro +2 more
openaire +7 more sources
Journal of International Medical Research, 2019 The heart is one of the organs most vulnerable to sepsis. This review describes the general characteristics of sepsis-induced cardiomyopathy and the main pathogenesis of myocardial dysfunction in sepsis.
Fei Yang +3 more
doaj +1 more source
Journal of Cardiothoracic Surgery, 2022 Objective Investigate the safety and efficacy of preoperative levosimendan in patients undergoing left ventricular assist device (LVAD) implantation.
Amitai Segev +9 more
doaj +1 more source
Effect of levosimendan on haemodynamics of mechanically Ventillated patient .
Minia Journal of Medical ResearchBackground: Levosimendan is an inodilator medication that, given its distinctive pharmacological actions and safety profile, represents an appropriate treatment in cases with heart failure with a decreased ejection fraction in the advanced stage of the ...
Sara Zaki +3 more
doaj +1 more source
Clinical Case Reports, Volume 13, Issue 12, December 2025.Mitral anterolateral papillary muscle rupture with partial valve body prolapse and severe mitral regurgitation after acute myocardial infarction (ultrasound schematic). ABSTRACT Due to dual blood supply, ischemic mitral anterolateral papillary muscle rupture is less common than that of posteromedial papillary muscle and is rare in acute myocardial ...
Zeyan Liu +4 more
wiley +1 more source
Clinical Cardiology, Volume 48, Issue 12, December 2025.The CYP3A5 rs776746 CC genotype is a strong biomarker for ticagrelor‐induced dyspnea, conferring a 2.3‐fold higher risk. Genotype‐guided antiplatelet therapy may mitigate this adverse reaction, enabling personalized treatment for ACS patients. ABSTRACT Background Dual antiplatelet therapy with aspirin and a P2Y₁₂ inhibitor is standard for patients with
Yanming Zhang +5 more
wiley +1 more source